Pretomanid A FDA approved new treatment for highly treatmentresistant tuberculosis TB of lungs

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=UDUJ2ZaBwW0

Pretomanid: A FDA approved treatment for highly treatment-resistant tuberculosis (TB) of the lungs • Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis is usually can be treated effectively by anti-tuberculosis medicines But The bacterium that causes tuberculosis can develop resistance to the antibiotics used to treat it. Multidrug-resistant TB and extensively drug-resistant TB are public health threats due to limited treatment options. New treatments are important to meet patient national and global health needs. • This video contains information of a new drug which has been recently approved by FDA for treatment for highly treatment-resistant tuberculosis (TB) of the lungs. • The term drug-resistant TB refers to cases of TB caused by an isolate of Mycobacterium tuberculosis that is resistant to one of the first-line anti-TB drugs: isoniazid, rifampin, pyrazinamide, ethambutol, or streptomycin. • Multidrug-resistant TB (MDR-TB) is TB that does not respond to at least isoniazid and rifampicin, the 2 most powerful anti-TB drugs. • Extensively drug-resistant TB, XDR-TB, is a form of multidrug-resistant TB with additional resistance to more anti-TB drugs that therefore responds to even fewer available medicines. It has been reported in 117 countries worldwide. The overall prognosis for adults with XDR-TB is poor with high mortality. According to the World Health Organization, in 2016, there were an estimated 490,000 new cases of multidrug-resistant TB worldwide. It is estimated that about 6.2% of these cases were XDR-TB. • Multidrug-resistant TB and extensively drug-resistant TB are difficult to treat due to resistance to available therapies. • The U.S. Food and Drug Administration in Aug 2019 approved Pretomanid in combination with bedaquiline and linezolid for treating a limited and specific population of adult patients with extensively drug resistant, treatment-intolerant or nonresponsive multidrug resistant pulmonary TB. • Pretomanid is an antibacterial drug of the nitroimidazole class. Pretomanid has been developed and clinically evaluated by TB Alliance, a not-for-profit product development partnership dedicated to the discovery and development of new, faster-acting and affordable medicines for tuberculosis (TB). • Pretomanid is the second drug to be approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, or LPAD pathway, established to advance development and approval of antibacterial and antifungal drugs to treat serious or life-threatening infections in a limited population of patients with unmet need. • Pretomanid also received the FDA’s Qualified Infectious Disease Product (QIDP) designation. • The FDA granted Pretomanid Tablets Priority Review. • The FDA also granted Pretomanid Tablets an Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. • The most common adverse reactions observed in patients treated with Pretomanid in combination with bedaquiline and linezolid included damage to the nerves (peripheral neuropathy), acne, anemia, nausea, vomiting, headache, increased liver enzymes (transaminases and gamma-glutamyltransferase), indigestion (dyspepsia), rash, increased pancreatic enzymes (hyperamylasemia), visual impairment, low blood sugar (hypoglycemia), and diarrhea. • Pretomanid used in combination with bedaquiline and linezolid should not be used in patients with hypersensitivity to bedaquiline or linezolid. • Thank You for watching this video. • I hope this information will be helpful to you. • If you still not subscribed my channel, please subscribe for more such videos. • If you have any comments or questions, please write in comments section, I will definitely try to find out answer of your question. • Please share this video with your friends and do not forget to hit the like button. • Please visit my website: http://www.medicalinfo4u.com/ • Check out my other videos: • Vyleesi (bremelanotide)- New Female Version of Viagra approved by FDA: • Video • Orilissa / Elagolix: FDA approved New drug for endometriosis: • Orilissa / Elagolix: FDA approved New... • FDA approved new drug SKYRIZI (risankizumab) for Plaque Psoriasis: an interleukin-23 inhibitor: • Skyrizi (risankizumab): mechanism of ... • FDA approves nasal glucagon for treatment of severe hypoglycemia: • FDA approves nasal glucagon for treat... • RINVOQ (upadacitinib): A new FDA approved AbbVie medicine for treatment of rheumatoid arthritis: • Rinvoq (upadacitinib): indication, me... • #MedicalInfo4U • #XDRTBtreatment • #Pretomanid • #tuberculosistreatment • #TBtreatment • MDRTBtreatment • #FDAapprovedmedicine • #newmedicine

#############################

New on site